Key Takeaways
- • UK biotech venture capital investment surged 17% quarter-over-quarter in Q1 2026, reaching £516 million, signaling sustained recovery after a challenging 2025 that saw a 13.2% annual decline to £1.79 billion across 58 deals.
- • Deal activity accelerated dramatically with 24 transactions completed in Q1 2026, a 60% increase from 15 deals in Q1 2025, reflecting a broader distribution of capital across companies rather than concentration in megadeals.
- • The UK maintained its position as Europe's leading biotech market, capturing 30% of all European venture financing in 2025 despite macroeconomic headwinds and major pharma pullbacks from the region.
- • Strategic M&A activity remained robust, with Eli Lilly acquiring Centessa Pharmaceuticals for £4.6 billion and Amgen acquiring Dark Blue Therapeutics for £626 million, demonstrating sustained international investor appetite for UK biotech assets.
- • IPO markets remain dormant, with zero UK biotech IPOs in Q1 2026, continuing an extended period of public market inactivity that constrains liquidity options for growth-stage companies.
Summary
UK biotech venture capital demonstrated resilience and momentum in the first quarter of 2026, with investments reaching £516 million—a 17% sequential increase from £442 million in Q4 2025. This quarter-over-quarter expansion represents a notable reversal following 2025's challenging environment, when UK biotech venture capital declined 13.2% year-over-year to £1.79 billion across 58 deals. According to the BioIndustry Association's latest data, the recovery is underpinned by a fundamental shift in deal composition: Q1 2026 recorded 24 transactions, a 60% surge from just 15 deals in the same period last year, indicating broader-based investor participation rather than reliance on a handful of large rounds.
The composition of capital distribution in Q1 2026 differs meaningfully from the prior year. While total funding of £552 million in aggregate equity financing remains below Q1 2025's £924 million—heavily influenced by megadeals in that earlier period—the underlying investment environment has strengthened substantially. Excluding the disproportionate impact of those exceptional transactions, current investment levels show genuine expansion in investor activity across the funding spectrum. Jane Wall, Managing Director of the BIA, characterized the current environment as "an extremely challenging time for biotech," yet the metrics reflect gradual stabilization and renewed confidence in the sector's fundamentals.
Despite the recovery in venture capital, public markets remain a significant constraint. Follow-on financing totaled only £36 million in Q1 2026, up modestly from £24 million in Q4 2025, while IPO activity remained entirely dormant—no UK biotech companies achieved public listings in the quarter. This absence of liquidity events in public markets underscores the bifurcated nature of current investor sentiment: private capital increasingly targeted UK biotech, yet institutional and retail investors remain absent from equity offerings.
Mergers and acquisitions activity provided a countervailing indicator of sector strength. Eli Lilly's £4.6 billion acquisition of Centessa Pharmaceuticals and Amgen's £626 million purchase of Dark Blue Therapeutics demonstrate sustained international appetite for UK-developed biotech assets. These transactions reflect global pharmaceutical majors' willingness to deploy substantial capital for proven assets and clinical-stage pipelines, even as conventional fundraising and exit pathways remain constrained. The BIA's data suggests the UK enters the second quarter of 2026 with "renewed momentum and increased investor confidence," supported by a broadening investor base willing to deploy capital across earlier and mid-stage companies.
The composition of capital distribution in Q1 2026 differs meaningfully from the prior year. While total funding of £552 million in aggregate equity financing remains below Q1 2025's £924 million—heavily influenced by megadeals in that earlier period—the underlying investment environment has strengthened substantially. Excluding the disproportionate impact of those exceptional transactions, current investment levels show genuine expansion in investor activity across the funding spectrum. Jane Wall, Managing Director of the BIA, characterized the current environment as "an extremely challenging time for biotech," yet the metrics reflect gradual stabilization and renewed confidence in the sector's fundamentals.
Despite the recovery in venture capital, public markets remain a significant constraint. Follow-on financing totaled only £36 million in Q1 2026, up modestly from £24 million in Q4 2025, while IPO activity remained entirely dormant—no UK biotech companies achieved public listings in the quarter. This absence of liquidity events in public markets underscores the bifurcated nature of current investor sentiment: private capital increasingly targeted UK biotech, yet institutional and retail investors remain absent from equity offerings.
Mergers and acquisitions activity provided a countervailing indicator of sector strength. Eli Lilly's £4.6 billion acquisition of Centessa Pharmaceuticals and Amgen's £626 million purchase of Dark Blue Therapeutics demonstrate sustained international appetite for UK-developed biotech assets. These transactions reflect global pharmaceutical majors' willingness to deploy substantial capital for proven assets and clinical-stage pipelines, even as conventional fundraising and exit pathways remain constrained. The BIA's data suggests the UK enters the second quarter of 2026 with "renewed momentum and increased investor confidence," supported by a broadening investor base willing to deploy capital across earlier and mid-stage companies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.